publication date: Jun. 5, 2015

NCI-MATCH to Bring in Public, Private Funds, Giving NCI New Urgent Scientific Agenda


ECOG-ACRIN Cancer Research Group is starting enrollment in NCI-MATCH, the most ambitious of NCI’s new generation of clinical trials.

In addition to being the centerpiece of the institute’s recently formed National Clinical Trials Network, NCI-MATCH—the name is an acronym for Molecular Analysis for Therapy Choice—provides a strong case for garnering Congressional support for the White House precision medicine initiative.

The $215 million program proposed by Obama as part of appropriations for fiscal 2016 hasn’t translated into congressional appropriations. The PMI budget request includes $70 million for NCI to scale up efforts to identify genomic drivers in cancer and apply that knowledge to develop more effective approaches to cancer treatment. Similarly, the new-generation trials would boost the NCI case in pursuit of a share of another potential windfall: the 21st Century Cures.

“We hope to—if we are fortunate enough to receive the resources that have been requested from Congress—to be able to leverage this particular trial as well as our other precision medicine trials to develop NCI-MATCH-like studies in which we can go deeper into particular diseases based on the early signals we get from this investigation,” said James Doroshow, director of the NCI Division of Cancer Treatment and Diagnosis.

Doroshow spoke at the June 1 press conference at the annual meeting of the American Society of Clinical Oncology, where NCI-MATCH was unveiled. His conversation with The Cancer Letter appears on p. 1.

NCI-MATCH has the … Continue reading 41-22 NCI-MATCH to Bring in Public, Private Funds, Giving NCI New Urgent Scientific Agenda

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.